Targeted 595 ‐gene genomic profiling demonstrates low tumor mutational burden in olfactory neuroblastoma
ConclusionTMB is a novel biomarker guiding the classification of neoplasms in the emerging era of immunotherapy. The characterization of ONB as a low ‐TMB pathology contributes to the overall taxonomy of all cancers and suggests limited utility of immunotherapy treatment.
Source: International Forum of Allergy and Rhinology - Category: Allergy & Immunology Authors: Jacob Friedman,
Jane K. Schumacher,
Pete Papagiannopoulos,
Samer Al ‐Khudari,
Bobby A. Tajudeen,
Pete S. Batra Tags: ORIGINAL ARTICLE Source Type: research
More News: Allergy | Allergy & Immunology | Brain | Cancer | Cancer & Oncology | Clinical Trials | Environmental Health | Genetics | Immunotherapy | Neuroblastoma | Neurology | Pathology